Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases

Cardiometabolic diseases (CMDs) are a group of metabolic abnormalities that increase the risk of diseases such as type 2 diabetes, cardiovascular diseases, insulin resistance, non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and abdominal obesity. The study of CMDs’ comorbidity is an emergin...

Full description

Saved in:
Bibliographic Details
Main Authors: Faith Ogbonnaya, Olutayo S. Shokunbi
Format: Article
Language:English
Published: College of Medicine, Al-Nahrain University 2025-05-01
Series:Baghdad Journal of Biochemistry and Applied Biological Sciences
Subjects:
Online Access:https://bjbabs.org/index.php/bjbabs/article/view/287
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849686998891102208
author Faith Ogbonnaya
Olutayo S. Shokunbi
author_facet Faith Ogbonnaya
Olutayo S. Shokunbi
author_sort Faith Ogbonnaya
collection DOAJ
description Cardiometabolic diseases (CMDs) are a group of metabolic abnormalities that increase the risk of diseases such as type 2 diabetes, cardiovascular diseases, insulin resistance, non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and abdominal obesity. The study of CMDs’ comorbidity is an emerging field. In the quest to reduce the cost and side effects of drugs, fasting therapies like the ketogenic diet (KD) have been proposed for treating seizure disorders, cancer, and chronic diseases. Recently, it has been reported to improve the quality of life of patients with cardiometabolic-related diseases. KD is a very low-carbohydrate, high-protein, very high-fat diet that induces ketogenesis, eliciting molecular signals. Intake of KD produces inhibition of histone deacetylase and 3-hydroxy-3-methyl glutaryl coA (HMG-CoA) reductase. It also increases the particulate size of low density lipoprotein cholesterol (LDL-C), lipolysis, HMG-CoA synthase 2, cataplerotic activity, high-density lipoprotein, and sirtuin production, which results in improved health status for patients with NAFLD, diabetes, and cardiovascular diseases when KD is consumed for a minimum of two weeks. There are usually mild side effects that are experienced with this therapy, but these can be overcome after four (4) weeks of continuous intake of KD and with certain interventions like vitamins, minerals, and calcium. There is, therefore, a need to explore ways of incorporating KD into the clinical management and treatment of cardiometabolic diseases globally.
format Article
id doaj-art-2f750aff7ff94b548b76e1ecea74ab1a
institution DOAJ
issn 2706-9915
language English
publishDate 2025-05-01
publisher College of Medicine, Al-Nahrain University
record_format Article
series Baghdad Journal of Biochemistry and Applied Biological Sciences
spelling doaj-art-2f750aff7ff94b548b76e1ecea74ab1a2025-08-20T03:22:30ZengCollege of Medicine, Al-Nahrain UniversityBaghdad Journal of Biochemistry and Applied Biological Sciences2706-99152025-05-0162657710.47419/bjbabs.v6i02.287Effect of Ketogenic Diet on Selected Cardiometabolic-Related DiseasesFaith Ogbonnaya0Olutayo S. Shokunbi1Biochemistry, School of Basic Medical Sciences, Babcock University, Ilishan, NigeriaBiochemistry, School of Basic Medical Sciences, Babcock University, Ilishan, NigeriaCardiometabolic diseases (CMDs) are a group of metabolic abnormalities that increase the risk of diseases such as type 2 diabetes, cardiovascular diseases, insulin resistance, non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and abdominal obesity. The study of CMDs’ comorbidity is an emerging field. In the quest to reduce the cost and side effects of drugs, fasting therapies like the ketogenic diet (KD) have been proposed for treating seizure disorders, cancer, and chronic diseases. Recently, it has been reported to improve the quality of life of patients with cardiometabolic-related diseases. KD is a very low-carbohydrate, high-protein, very high-fat diet that induces ketogenesis, eliciting molecular signals. Intake of KD produces inhibition of histone deacetylase and 3-hydroxy-3-methyl glutaryl coA (HMG-CoA) reductase. It also increases the particulate size of low density lipoprotein cholesterol (LDL-C), lipolysis, HMG-CoA synthase 2, cataplerotic activity, high-density lipoprotein, and sirtuin production, which results in improved health status for patients with NAFLD, diabetes, and cardiovascular diseases when KD is consumed for a minimum of two weeks. There are usually mild side effects that are experienced with this therapy, but these can be overcome after four (4) weeks of continuous intake of KD and with certain interventions like vitamins, minerals, and calcium. There is, therefore, a need to explore ways of incorporating KD into the clinical management and treatment of cardiometabolic diseases globally.https://bjbabs.org/index.php/bjbabs/article/view/287ketogenic diettype 2 diabetes mellituscardiometabolic disease
spellingShingle Faith Ogbonnaya
Olutayo S. Shokunbi
Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
Baghdad Journal of Biochemistry and Applied Biological Sciences
ketogenic diet
type 2 diabetes mellitus
cardiometabolic disease
title Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
title_full Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
title_fullStr Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
title_full_unstemmed Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
title_short Effect of Ketogenic Diet on Selected Cardiometabolic-Related Diseases
title_sort effect of ketogenic diet on selected cardiometabolic related diseases
topic ketogenic diet
type 2 diabetes mellitus
cardiometabolic disease
url https://bjbabs.org/index.php/bjbabs/article/view/287
work_keys_str_mv AT faithogbonnaya effectofketogenicdietonselectedcardiometabolicrelateddiseases
AT olutayosshokunbi effectofketogenicdietonselectedcardiometabolicrelateddiseases